Hims & Hers – BiotechReality – Information Intelligence System for Biopharma

Quick Summary Strategic Partnership & Settlement: Novo Nordisk and Hims & Hers have reached a landmark agreement to offer FDA-approved Ozempic® and Wegovy® (including the new Wegovy® pill) via the telehealth platform, resulting in the dismissal of Novo Nordisk's patent infringement lawsuit. Pivoting from Compounding: Hims & Hers will cease all advertising and sales of compounded GLP-1s, shifting its business model entirely toward branded, FDA-approved medications at competitive self-pay prices. Oral Weight-Loss Breakthrough: The deal highlights the launch of the Wegovy® pill, which demonstrated a $16.6\%$ average weight loss in clinical trials (OASIS 4), providing a potent oral alternative to traditional weekly injections for obesity and cardiovascular risk reduction. PLAINSBORO, N.J. - In a move that signals a major shift in the telehealth weight-loss landscape, Novo Nordisk (NVO) and Hims & Hers Health, Inc. (HIMS) announced a definitive agreement today to provide direct access to FDA-approved Ozempic® and Wegovy®, including the newly launched Wegovy® pill on the Hims & Hers platform. The partnership effectively ends a high-stakes legal battle between the pharmaceutical giant and the telehealth leader. As part of the settlement, Novo Nordisk has agreed to dismiss its patent infringement lawsuit against Hims & Hers, which was filed last month following Hims' attempt to launch a compounded version of the oral weight-loss medication. A New Chapter for Telehealth Access Under the terms of the agreement, which takes effect later this month, Hims & Hers will pivot its weight-loss business model away from unapproved compounded GLP-1s. Instead, the platform will offer the full suite of branded Novo Nordisk semaglutide products at self-pay prices consistent with other major telehealth providers. The rollout includes: Ozempic® Injection: 0.5 mg, 1 mg, and 2 mg doses for Type 2 diabetes and cardiovascular risk reduction. Wegovy® Injection: All standard doses ranging from 0.25 mg to 2.4 mg. Wegovy® Pill: The first-of-its-kind oral GLP-1, available in 1.5 mg, 4 mg, 9 mg, and 25 mg tablets. This agreement is a meaningful win for patients, By expanding access through leading digital care platforms, we are helping to connect more people with FDA-approved medicines that have been rigorously evaluated for safety and efficacy. Mike Doustdar, President and CEO of Novo Nordisk Read More: Novo Nordisk Announces Significant Price Reduction on Wegovy & Ozempic The "Wegovy Pill" Advantage: Results from OASIS 4 A central pillar of this deal is the inclusion of the Wegovy® pill, which received FDA approval in late 2025. Data from the OASIS 4 phase 3 trial underscored the pill's efficacy, positioning it as a potent alternative to weekly injections. MetricWegovy® Pill (25 mg)Placebo*Mean Weight Loss (Idealized Scenario) **16.6%2.7%Mean Weight Loss (Real-World Scenario)13.6%2.4%Achieved ≥5% Weight Loss76%31% Moving Away from Compounding The deal marks a significant "about-face" for Hims & Hers. The company will immediately cease advertising compounded GLP-1 offerings and has established a clinical pathway for existing patients to transition to the FDA-approved branded alternatives. While the lawsuit has been dismissed, Novo Nordisk noted it reserves the right to refile in the future, maintaining a "trust but verify" stance on the telehealth company’s commitment to branded-only distribution. For Hims & Hers, the partnership grants them a stable, legitimate supply of the world's most in-demand medications, resolving the regulatory uncertainty that has pressured their stock in recent months. Novo Nordisk Last Modified:

Tag: Hims & Hers

Novo Nordisk and Hims & Hers Legal Agreement with Landmark GLP-1 Supply Deal

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment